Immutep (IMMP) Notes Payables (2012 - 2025)

Immutep's (IMMP) quarterly Notes Payables came in at $330323.8 in Q4 2025, down 42.11% quarter-over-quarter from $570627.2 in Q4 2014.

Analysis

Immutep (IMMP) Notes Payables (2012 - 2025) Analysis & Trends

Immutep (IMMP) has reported Notes Payables for 4 consecutive years, with $330323.8 the latest figure, recorded in Q4 2025.

For the quarter ending Q4 2025, Notes Payables changed N/A year-over-year to $330323.8; the trailing twelve-month figure through Dec 2025 stood at $330323.8 (changed N/A YoY), and the FY2012 full-year result was $1.5 million, changed N/A from the prior year.
Notes Payables eased to $330323.8 in Q4 2025 per IMMP's latest filing, from $570627.2 in the prior quarter.
Across five years, Notes Payables topped out at $330323.8 in Q4 2025 and bottomed at $330323.8 in Q4 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Amgen	211.73 Bn	197.74 Bn	7.24 Bn
2	Gilead Sciences	180.92 Bn	177.74 Bn	6.22 Bn
3	Vertex Pharmaceuticals	132.16 Bn	124.30 Bn	2.84 Bn
4	Regeneron Pharmaceuticals	82.89 Bn	74.90 Bn	3.93 Bn
5	Argenx Se	61.41 Bn	56.23 Bn	1.37 Bn
6	Moderna	53.99 Bn	48.85 Bn	52.00 Mn
7	Alnylam Pharmaceuticals	34.48 Bn	31.18 Bn	992.69 Mn
8	Biogen	31.15 Bn	29.86 Bn	1.96 Bn
9	Roivant Sciences	30.05 Bn	30.05 Bn	1.16 Mn
10	Immutep	51.68 Mn	51.68 Mn	-

Historic Data

Download Data